N C Tebbutt

Summary

Affiliation: Ludwig Institute for Cancer Research
Country: Australia

Publications

  1. pmc Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
    D Damianovich
    Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia
    Br J Cancer 96:546-50. 2007
  2. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
  3. pmc An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
    Stephen Clarke
    Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    BMC Cancer 13:120. 2013
  4. pmc Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 108:771-4. 2013
  5. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
  6. pmc Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus
    Rachel A Davey
    Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
    Lipids Health Dis 5:29. 2006
  7. pmc Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
    Dusan Kotasek
    Adelaide Cancer Center, Level 1, Tennyson Centre, 520 South Road, Kurralta Park, SA 5037, Australia
    BMC Cancer 11:313. 2011
  8. doi request reprint Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    N C Tebbutt
    Department of Medical Oncology, Austin Health, Melbourne, Australia
    Ann Oncol 22:1834-8. 2011
  9. doi request reprint Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
  10. pmc Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 102:475-81. 2010

Collaborators

Detail Information

Publications14

  1. pmc Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis
    D Damianovich
    Ludwig Institute for Cancer Research, Austin Health, Melbourne, Victoria, Australia
    Br J Cancer 96:546-50. 2007
    ..Older patients (> or =70 years) had inferior survival no matter which drug was used as initial treatment. Analysis of the Australian HIC database provides a valuable means of assessing patterns of use and outcomes of new therapies...
  2. pmc The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors
    Lee S Rosen
    Department of Medicine, University of California Los Angeles, Santa Monica, CA, USA
    BMC Cancer 13:242. 2013
    ..Gallbladder toxicity, including cholecystitis, has been reported with motesanib, an orally administered small-molecule antagonist of VEGFRs 1, 2 and 3; PDGFR; and Kit. We assessed effects of motesanib on gallbladder size and function...
  3. pmc An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]
    Stephen Clarke
    Royal North Shore Hospital, St Leonards, NSW 2065, Australia
    BMC Cancer 13:120. 2013
    ....
  4. pmc Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 108:771-4. 2013
    ..No KRAS, BRAF or PIK3CA mutations were observed.Conclusion:Cetuximab and docetaxel achieve modest responses rates, but maintain comparable survival times to other salvage regimens with low rates of toxicity...
  5. doi request reprint Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer
    Andrew J Weickhardt
    Ludwig Institute for Cancer Research, Australia
    J Clin Oncol 30:1505-12. 2012
    ..This preclinical and phase II study evaluated the efficacy and safety of the combination of cetuximab and erlotinib in metastatic colorectal cancer (mCRC)...
  6. pmc Severe combined hyperlipidaemia and retinal lipid infiltration in a patient with Type 2 diabetes mellitus
    Rachel A Davey
    Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
    Lipids Health Dis 5:29. 2006
    ..Type 2 DM plays a vital role both in allowing expression of severe combined hyperlipoproteinaemia, in addition to serving as a risk factor for complications such as tissue infiltration...
  7. pmc Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
    Dusan Kotasek
    Adelaide Cancer Center, Level 1, Tennyson Centre, 520 South Road, Kurralta Park, SA 5037, Australia
    BMC Cancer 11:313. 2011
    ....
  8. doi request reprint Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    N C Tebbutt
    Department of Medical Oncology, Austin Health, Melbourne, Australia
    Ann Oncol 22:1834-8. 2011
    ..Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab...
  9. doi request reprint Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    Niall C Tebbutt
    Austin Health, Studley Rd, Heidelberg, Victoria, 3084, Australia
    J Clin Oncol 28:3191-8. 2010
    ..To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial...
  10. pmc Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
    N C Tebbutt
    Department of Medical Oncology, Austin Health, PO Box 5555, Studley Road, Heidelberg, Melbourne, Victoria 3084, Australia
    Br J Cancer 102:475-81. 2010
    ..Weekly docetaxel is associated with less haematological toxicity. This randomised phase II study tested weekly docetaxel-based combination chemotherapy regimens, with the aim of maintaining their activity while reducing toxicity...
  11. doi request reprint Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
    T J Price
    Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, Australia
    Ann Oncol 23:1531-6. 2012
    ..We used the MAX population to investigate whether age affected the improved outcome found in CRC when bevacizumab is added to capecitabine chemotherapy...
  12. doi request reprint A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer
    M Michael
    Division of Cancer Medicine, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Victoria 8006, Australia
    Cancer Chemother Pharmacol 71:321-30. 2013
    ..This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities...
  13. pmc Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity
    G Chong
    Austin Health, Heidelberg, Vic, Australia
    Ther Adv Med Oncol 2:309-17. 2010
    ..Further randomized data, particularly for patients with potentially resectable liver metastases, are required in order to fully define the role of bevacizumab in the increasingly complex management paradigm for this disease...
  14. doi request reprint 18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma
    A Azad
    Ludwig Institute Oncology Unit, University of Melbourne, Austin Hospital, Austin Health, Melbourne, Vic, Australia
    Med Oncol 27:230-2. 2010
    ....